Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in:  The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Biotech Stock Mailbag: Arena Pharma, Agenus, EnteroMedics

thestreet.com — BOSTON ( TheStreet) -- The Biotech Stock Mailbag is nine years old. SThomas65 writes, "Your knee-jerk hatred for Arena Pharmaceuticals is blinding you to the huge potential of [APD334]. This drug could easily be the best of the bunch and generate billions of dollars in sales for Arena."

8 Biotech Stock Controversies Emerging From 'JPM15' Conference

thestreet.com — BOSTON ( TheStreet) -- The biotech sector typically outperforms the broader market during the week of the much-heralded J.P. Morgan Healthcare Conference. This year was no exception. Last week, the Nasdaq Biotechnology Index rose 1.4% compared with a 1.2% loss for the S&P 500. The J.P. Morgan conference is now in the rear-view mirror.

Express Scripts CEO: Amgen, Regeneron, Cancer Drugs Next Targets for Drug Discounting

thestreet.com — SAN FRANCISCO (TheStreet) -- Express Scripts CEO George Paz didn't mince words during his talk Tuesday at the J.P. Morgan Healthcare Conference. The big pharmacy benefits manager believes an aggressive strategy of negotiating discounts for specialty drugs -- and using formulary exclusions when it can't get those price cuts -- is reducing healthcare costs, Paz said.

Aegerion Target of SEC Probe Related to Drug Sales Practices

thestreet.com — Stocks in this article: AEGR The Securities and Exchange Commission is investigating Aegerion Pharmaceuticals . Funny, but Aegerion CEO Marc Beer didn't mention the SEC probe during his Monday appearance at the J.P. Morgan Healthcare Conference. Instead, the company slipped the disclosure inside an 8-K filing last night: In late 2014, the Company received a request for information from the U.S.

BioMarin Shows Up Rival Sarepta During 'JPM15' Investor Presentation

thestreet.com — It's rare to hear a biotech CEO mention a competing company by name when speaking in public. Like politicians, CEOs would rather acknowledge their rivals with generalities. (( BioMarin Pharmaceuticals BMRN) CEO JJ Bienaime feels differently, apparently, because he just went directly after Sarepta Therapeutics SRPT) at the J.P.

MannKind Gets Little Love From Sanofi at 'JPM15' Presentation

thestreet.com — SAN FRANCISCO ( (( TheStreet) -- MannKind MNKD) CEO Al Mann is retiring and the inhaled insulin device Afrezza still has no publicly disclosed commercial launch date. Elias Zerhouni, Sanofi's SNY) president of R&D, just finished speaking at the J.P. Morgan Healthcare Conference.

Celgene Has 2020 Vision For Long Term Growth But Plays Safe for 2017

thestreet.com — SAN FRANCISCO ( TheStreet)-- Celgene CEO Bob Hugin just wrapped his presentation at the J.P. Morgan Healthcare Conference by reiterating 2017 financial guidance and offering new, longer-term guidance for 2020. For 2015, Celgene's updated guidance was generally in-line with expectations on the top line, lower on the bottom line.

Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year

thestreet.com — The 168-week eteplirsen clinical update from ((( Sarepta Therapeutics SRPT) this morning can be viewed two ways. The Duchenne muscular dystrophy (DMD) patients continue to walk more than three years after starting treatment with eteplirsen, with no significant side effects or tolerability issues. The drug appears to be slowing the progression of DMD.

Vertex Pharma To Start Next-Gen Cystic Fibrosis Drug Studies Earlier Than Expected

thestreet.com — Vertex Pharmaceuticals announced its 2015 business outlook on Sunday night, ahead of Monday's presentation at the J.P. Morgan Healthcare Conference. There were a some interesting tidbits offered: 1. Vertex did not announce results from the 12-week, phase II study of next-generation cystic fibrosis drug VX-661 combined with Kalydeco (those data are coming later in the quarter.)

Roche to Acquire Majority Stake in Cancer Genetic Test Maker Foundation Medicine

thestreet.com — CAMBRIDGE, Mass. ( TheStreet) -- Foundation Medicine will become majority-owned by Roche as part of a $1 billion-plus strategic partnership to expand the use of genetic testing in cancer drug research and treatment, the companies announced today. Roche's acquired stake in Foundation Medicine is priced at $50 per share, more than double the company's Friday closing price of $23.93.
More Articles →
Jan 26, 2015

@michael_gilman i like the fit of your gib, young man. You'll go far.

Jan 26, 2015

@Mac_Trader On your suggestion, I bought Firestone’s Union Jack and Double Jack. Drinking the Double now. Like it.

Jan 26, 2015

@CramersShirt I’ve made contingency plans for power outage, including boiling water in my fireplace to make coffee. WE WILL SURVIVE!

Jan 26, 2015

@CramersShirt Yes! There are sufficient hoppy IPAs in my fridge to sustain us for several days, in case we cannot venture out. Thx.

Learn how to connect with Adam on social media by joining Muck Rack Pro



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.


Share This Profile